SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Solid Biosciences Inc. (NasdaqGS: SLDB) breached their fiduciary duties to shareholders. On March 14, 2018, Solid Biosciences announced that it received notification from the U.S. Food and Drug Administration that the company's Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy had been placed on clinical hold. Since the disappointing news was announced, Solid Biosciences' stock has fallen over 67% to close at $8.50 per share on March 26, 2018—47% below the company's January 26, 2018 initial public offering price of $16 per share.
View this press release on the firm's Shareholder Rights Blog: www.robbinsarroyo.com/solid-biosciences-inc
Solid Biosciences Express Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
